33
Participants
Start Date
September 11, 2023
Primary Completion Date
January 22, 2025
Study Completion Date
January 31, 2025
Vaccine AnAPN1
AnAPN1 is a recombinant protein expressed in Escherichia coli. It consists of the UF6b construct, derived from the sequence of the Anopheles gambiae alanyl aminopeptidase N (XM\_318000.4) and will be formulated with or without Synthetic Glucopyranosyl Lipid A (GLA)- LSQ adjuvant. Route of administration is intramuscular.
Centre de Recherches Médicales de Lammbaréné, Lambaréné
Collaborators (1)
Global Health Innovative Technology Fund
OTHER
Centre de Recherche Médicale de Lambaréné
OTHER